Engineering Natural Killer Cells for Cancer Immunotherapy

Slides:



Advertisements
Similar presentations
Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease- Causing Point Mutations Renee P. Stokowski, David R. Cox The American.
Advertisements

Gene Preference in Maple Syrup Urine Disease Mary M. Nellis, Dean J. Danner The American Journal of Human Genetics Volume 68, Issue 1, Pages (January.
Telomerase Activity and Expression of Telomerase RNA Component and Telomerase Catalytic Subunit Gene in Cervical Cancer Kenji Nakano, Elizabeth Watney,
Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.
Jennifer G. Cheung, Krystyna Konopka, Nejat Düzgünes
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Volume 20, Issue 2, (February 2012)
209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.
446. Gender Differences in the Osteogenic & Chondrogenic Potential of Human Muscle- Derived Stem Cells In Vitro  Alex C. Scibetta, Andrea B. Liebowitz,
Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers  Melinda Mata, Stephen.
Immunosuppressive monoclonal antibodies: current and next generation
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
Genome-editing Technologies for Gene and Cell Therapy
627. Non-Invasive, Multimodal Imaging of Microvesicles with Metabolically Biotinylated, Membrane-Bound Gaussia Luciferase    Molecular Therapy  Volume.
Elizabeth Morris, Alex Scibetta, Aiping Lu, Xueqin Gao, Johnny Huard
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy    Molecular Therapy  Volume.
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
Hydrodynamic Gene Delivery: Its Principles and Applications
Direct Conversion of Skin Cells into Blood: Alchemy or Science?
Molecular Therapy  Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)
Evolving Gene Therapy in Primary Immunodeficiency
Volume 20, Issue 6, Pages (June 2012)
343. Benchtop DNA Synthesizer: Oligo-Templated Polymerization (OTP)
In This Issue Cell Volume 158, Issue 5, (August 2014)
Engineering Natural Killer Cells for Cancer Immunotherapy
Escaping the Valley of Death
John R. Martin, Christopher E. Nelson, Mukesh K
Volume 26, Issue 2, Pages (February 2018)
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Volume 25, Issue 1, Pages 5-7 (January 2017)
Volume 25, Issue 5, Pages (May 2017)
HCMV jogs the ‘memory’ of NK cells in HBV
724. Blood-Derived Endothelial Progenitor Cells Can Be Isolated With a Novel Method of Diluted Whole Blood Incubation with AMD3100-Induced Mobilization.
Genome-editing Technologies for Gene and Cell Therapy
Valder R Arruda, Patricia Favaro, Jonathan D Finn  Molecular Therapy 
In Search of Magic Bullets: The Golden Age of Immunotherapeutics
Premal Lulla, Carlos A. Ramos  Molecular Therapy 
Molecular Therapy  Volume 20, (May 2012) DOI: /S (16)
Molecular Therapy  Volume 7, Issue 5, (May 2003) DOI: /S (16)
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Designer Lipids Advance Systemic siRNA Delivery
Volume 25, Issue 5, Pages (May 2017)
Volume 20, Issue 6, Pages (June 2012)
133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy    Molecular.
Erratum The American Journal of Human Genetics
660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy  Geeta Shroff  Molecular Therapy 
Volume 26, Issue 2, Pages (February 2018)
68. Site Specific Intra-Placental Gene Transfer Corrects Fetal Growth Restriction in a Novel Mouse Model of Placental Insufficiency (PI)    Molecular.
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
Jennifer G. Cheung, Krystyna Konopka, Nejat Düzgünes
405. Hindlimb and Forelimb Strength Assessment in a Canine Model of X-Linked Myotubular Myopathy Following AAV-Mediated Gene Replacement    Molecular.
Volume 26, Issue 4, Pages (April 2018)
674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)
521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS  Brad E. Hoffman  Molecular.
773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?
Shigeki Yagyu, Malcolm K. Brenner
History of Oncolytic Viruses: Genesis to Genetic Engineering
86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy    Molecular Therapy  Volume 20, Pages S35-S36.
Volume 26, Issue 5, Pages (May 2018)
Morton J Cowan, Hans-Peter Kiem  Molecular Therapy 
Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?
Cytokine Gene Therapy for Malignant Pleural Mesothelioma
Shirley Wong, Roderick A. Slavcev
624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results    Molecular.
Presentation transcript:

Engineering Natural Killer Cells for Cancer Immunotherapy Katayoun Rezvani, Rayne Rouce, Enli Liu, Elizabeth Shpall  Molecular Therapy  Volume 25, Issue 8, Pages 1769-1781 (August 2017) DOI: 10.1016/j.ymthe.2017.06.012 Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 1 Mechanisms of NK-Mediated Cytotoxicity (A) Spontaneous cytotoxicity. (B) Cytokine release. (C) ADCC. (D) Genetic modification. ADCC, antibody-dependent cell-mediated cytotoxicity; mAb, monoclonal antibody. Molecular Therapy 2017 25, 1769-1781DOI: (10.1016/j.ymthe.2017.06.012) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.